Shi, G., Huang, X., Wen, T., Song, T., Kuang, M., Mou, H., . . . Zhou, J. (2023, February). Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study. Cancer Medicine.
Chicago Style (17th ed.) CitationShi, Guo‐Ming, et al. "Pemigatinib in Previously Treated Chinese Patients with Locally Advanced or Metastatic Cholangiocarcinoma Carrying FGFR2 Fusions or Rearrangements: A Phase II Study." Cancer Medicine Feb. 2023.
MLA (9th ed.) CitationShi, Guo‐Ming, et al. "Pemigatinib in Previously Treated Chinese Patients with Locally Advanced or Metastatic Cholangiocarcinoma Carrying FGFR2 Fusions or Rearrangements: A Phase II Study." Cancer Medicine, Feb. 2023.
Warning: These citations may not always be 100% accurate.